Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019204 (
hepatocellular carcinoma
)
71,386
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Since its discovery in 1989, efforts to grow clinical isolates of the hepatitis C virus (HCV) in cell culture have met with limited success. Only the JFH-1 isolate has the capacity to replicate efficiently in cultured
hepatoma
cells without cell culture-adaptive mutations. We hypothesized that cultured cells lack one or more factors required for the replication of clinical isolates. To identify the missing factors, we transduced Huh-7.5 human
hepatoma
cells with a pooled lentivirus-based human complementary DNA (cDNA) library, transfected the cells with HCV subgenomic replicons lacking adaptive mutations, and selected for stable replicon colonies. This led to the identification of a single cDNA,
SEC14L2
, that enabled RNA replication of diverse HCV genotypes in several
hepatoma
cell lines. This effect was dose-dependent, and required the continuous presence of
SEC14L2
. Full-length HCV genomes also replicated and produced low levels of infectious virus. Remarkably,
SEC14L2
-expressing Huh-7.5 cells also supported HCV replication following inoculation with patient sera. Mechanistic studies suggest that
SEC14L2
promotes HCV infection by enhancing vitamin E-mediated protection against lipid peroxidation. This provides a foundation for development of in vitro replication systems for all HCV isolates, creating a useful platform to dissect the mechanisms by which cell culture-adaptive mutations act.
...
PMID:SEC14L2 enables pan-genotype HCV replication in cell culture. 2748 Jun 78
Hepatitis C virus (HCV) genotype (GT) 3 is the second most prevalent of the seven HCV genotypes and exhibits the greatest resistance to the highly potent, direct-acting antivirals (DAAs) that are currently in use. Previously a stable cell line harbouring the S52 GT3 sub-genomic replicon (SGR) was established, but this SGR was unable to robustly replicate transiently. As transient SGRs are a critical tool in the development of DAAs, and in the study of viral resistance, we sought to establish a transient SGR system based on S52. Next-generation sequencing was used to identify putative culture-adaptive substitutions that had arisen during long-term selection of the S52 SGR. A subset of these substitutions was built back into the S52 SGR in the context of a CpG/UpA-low luciferase reporter, with a single point mutation in NS4A conferring the greatest replication capability upon S52. Modification of the innate immune-sensing pathways of Huh7.5
hepatoma
cells by expression of the parainfluenza virus type 5 V protein and
SEC14L2
resulted in a further enhancement of S52 replication. Furthermore, this transiently replicating SGR showed genotype-specific differences in sensitivity to two clinically relevant NS5A DAAs. In conclusion, we report that a single substitution in NS4A, coupled with host cell modifications, enabled robust levels of transient replication by the GT3 S52 SGR. This system will have beneficial uses in both basic research into the unique aspects of GT3 biology and drug discovery.
...
PMID:Manipulation of both virus- and cell-specific factors is required for robust transient replication of a hepatitis C virus genotype 3a sub-genomic replicon. 2898 38
Identification of master regulator (MR) genes offers a relatively rapid and efficient way to characterize disease-specific molecular programs. Since strong consensus regarding commonly altered MRs in
hepatocellular carcinoma
(
HCC
) is lacking, we generated a compendium of
HCC
datasets from 21 studies and identified a comprehensive signature consisting of 483 genes commonly deregulated in
HCC
. We then used reverse engineering of transcriptional networks to identify the MRs that underpin the development and progression of
HCC
. After cross-validation in different
HCC
datasets, systematic assessment using patient-derived data confirmed prognostic predictive capacities for most
HCC
MRs and their corresponding regulons. Our
HCC
signature covered well-established liver cancer hallmarks, and network analyses revealed coordinated interaction between several MRs. One novel MR,
SEC14L2
, exerted an anti-proliferative effect in
HCC
cells and strongly suppressed tumor growth in a mouse model. This study advances our knowledge of transcriptional MRs potentially involved in
HCC
development and progression that may be targeted by specific interventions.
...
PMID:Discovering master regulators in hepatocellular carcinoma: one novel MR, SEC14L2 inhibits cancer cells. 3185 20